PDT Partners LLC Has $5 Million Holdings in Insulet Co. (NASDAQ:PODD)

PDT Partners LLC trimmed its holdings in shares of Insulet Co. (NASDAQ:PODD) by 33.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,492 shares of the medical instruments supplier’s stock after selling 10,800 shares during the period. Insulet accounts for approximately 0.4% of PDT Partners LLC’s holdings, making the stock its 27th largest holding. PDT Partners LLC’s holdings in Insulet were worth $5,002,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of PODD. QRG Capital Management Inc. acquired a new position in shares of Insulet during the third quarter valued at $297,000. Diversified Trust Co lifted its position in Insulet by 90.9% during the 2nd quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock valued at $1,842,000 after purchasing an additional 4,348 shares during the period. Linden Thomas Advisory Services LLC boosted its stake in shares of Insulet by 65.8% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 8,812 shares of the medical instruments supplier’s stock valued at $1,778,000 after purchasing an additional 3,497 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Insulet by 38.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 179,393 shares of the medical instruments supplier’s stock valued at $36,202,000 after purchasing an additional 50,101 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky grew its position in shares of Insulet by 23.9% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 35,035 shares of the medical instruments supplier’s stock worth $6,006,000 after buying an additional 6,754 shares during the period.

Wall Street Analyst Weigh In

PODD has been the topic of a number of analyst reports. Citigroup increased their price target on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. UBS Group raised their target price on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. Sanford C. Bernstein initiated coverage on Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target for the company. Barclays lifted their price objective on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Finally, Piper Sandler increased their target price on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Trading Down 0.1 %

NASDAQ:PODD opened at $266.78 on Friday. The company has a market cap of $18.71 billion, a P/E ratio of 45.68, a price-to-earnings-growth ratio of 4.08 and a beta of 1.22. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $279.40. The business has a 50 day moving average price of $243.79 and a two-hundred day moving average price of $213.11. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.